Navigation Links
UH Seidman Cancer Center researchers present at American Society of Hematology Annual Meeting
Date:12/10/2011

CLEVELAND: Researchers from Seidman Cancer Center at University Hospitals (UH) Case Medical Center and Case Western Reserve University School of Medicine presented new research findings in 25 presentations this weekend at the 53rd Annual Meeting of the American Society of Hematology (ASH) at the San Diego Convention Center.

"The breadth and depth of this innovative cancer research presented at ASH is truly outstanding," says Stan Gerson, MD, Director of the Seidman Cancer Center at UH Case Medical Center and the Case Comprehensive Cancer Center at Case Western Reserve University. "Our faculty members are making tremendous advances in hematology and oncology which is reflected in their being chosen for oral and poster presentations."

Speaking at the ASH "Scientific Symposium on Lymphoid Neoplasia" in a session titled "Autophagy and Metabolism in Lymphoid Malignancies," Clark Distelhorst, MD, provides a synthesis of the latest research indicating that autophagy occurs in lymphoid malignancies and may be a novel therapeutic target for lymphoma and other lymphoid neoplasia. His research suggests that targeting autophagy (a process through which cells eat parts of themselves to generate sufficient energy to stay alive) may be a useful adjunct to the longstanding use of glucocorticoids, such as prednisone, to kill cancer cells.

His session outlines the growing body of evidence that treatments aimed at inducing autophagy have great promise in treating lymphoid malignancies. In his session, Dr. Distelhorst presents important data explaining how glucocorticoids starve tumor cells of glucose and thus induce autophagy. Researchers at UH Case Medical Center and Case Western Reserve University identified the Dexamethasone-induced Gene 2 (dig2) that encodes a protein mediator of autophagy.

"This new cancer-fighting strategy lays the groundwork for further development of autophagy inhibitors to enhance the glucocorticoids properties," says Dr. Distelhorst, who is vice-chair of the ASH subcommittee on Lymphoid Neoplasia. "This is a major step forward in our research efforts to develop new therapies for lymphoid malignancies."

Dr. Distelhorst's session is Saturday, December 10, 4 p.m. - 5:30 p.m. in Room 6A. (San Diego Convention Center). http://ash.confex.com/ash/2011/webprogram/Paper35836.html

In a poster presentation (Abstract# 1907), Jeffery Auletta, MD, Kenneth Cooke, MD, and colleagues presented significant findings that mesenchymal stem cells (MSCs) effectively treat graft-versus-host disease (GvHD) while not interfering with bone marrow transplant's efficacy in treating leukemia.

MSCs are non-hematopoietic (not blood-forming cells) adult stem cells found in the bone marrow and were discovered at UH Seidman Cancer Center and Case Western Reserve University. They maintain hematopoietic stem cell (blood-forming cells) development and also differentiate into fat cells, bone cells and cartilage cells. MSCs have been shown to suppress immune responses ex vivo (outside the body in cell culture conditions).

Due to these properties, MSCs have been used to treat GvHD in bone marrow transplant (BMT) patients. However, how MSC immunomodulation works in vivo (inside the body) has not been well studied, and, in fact, could potentially promote leukemia/lymphoma recurrence in transplant patients. That is, the benefit of BMT is that the donor graft kills residual leukemia in the transplant recipient (host), a process called graft-versus-leukemia (GvL).

"We used a pre-clinical mouse model of BMT to study how human MSCs mediate in vivo immune effects," says Dr. Auletta. "Our results show for the first time using an animal model that human MSCs simultaneously attenuate GvHD, but spare GvL activity."

The poster titled "Human Mesenchymal Stem Cells Attenuate Graft-Versus-Host Disease and Maintain Graft-Versus-Leukemia in Murine Allogeneic Bone Marrow Transplantation" is Saturday, December 10, 5:30 p.m.-7:30 p.m. in Hall GH (San Diego Convention Center). http://ash.confex.com/ash/2011/webprogram/Paper39108.html

Co-authors are Saada Eid, BS, Matthew Keller, BS, Leland Metheny, MD, Rocio Guardia-Wolff, BS, Zhenghong Lee, PhD, and Luis A. Solchaga, PhD.
'/>"/>

Contact: Alicia Reale
alicia.reale@uhhospitals.org
216-533-0685
University Hospitals Case Medical Center
Source:Eurekalert

Related biology news :

1. University Hospitals Seidman Cancer Center tests novel drug that makes brain tumors glow hot pink
2. Breast cancer treatment resistance linked to signaling pathway
3. Jefferson scientists deliver toxic genes to effectively kill pancreatic cancer cells
4. The dietary supplement genistein can undermine breast cancer treatment
5. Saliva proteins could help detection of oral cancer
6. Vitamin C supplements may reduce benefit from wide range of anti-cancer drugs
7. Breakthrough optical technology to assess colon cancer risk, accuracy
8. Breast cancer cells recycle to escape death by hormonal therapy
9. Nanodiamond drug device could transform cancer treatment
10. Second lumpectomy for breast cancer reduces survival rates
11. Study looks at psychological impact of gene test for breast cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/16/2017)...  Veratad Technologies, LLC ( www.veratad.com ), an innovative ... verification solutions, announced today they will participate as a ... thru May 17, 2017, in Washington D.C.,s ... Identity impacts the lives of billions ... evolving digital world, defining identity is critical to nearly ...
(Date:4/18/2017)... , April 18, 2017  Socionext Inc., a global expert ... a media edge server, the M820, which features the company,s hybrid ... software provided by Tera Probe, Inc., will be showcased during the ... the NAB show at the Las Vegas ... ...
(Date:4/11/2017)... Research and Markets has announced the addition of the ... ... grow at a CAGR of 30.37% during the period 2017-2021. ... prepared based on an in-depth market analysis with inputs from industry ... over the coming years. The report also includes a discussion of ...
Breaking Biology News(10 mins):
(Date:6/19/2017)... ... June 19, 2017 , ... As Vice President, Product ... including training, implementation, support, and client process and SOP development. , Mr. Guinter ... held leadership roles for service providers and top-tier pharmaceuticals, and as an independent ...
(Date:6/19/2017)... (PRWEB) , ... June 19, 2017 , ... A colony ... among its cells and tissues by delivering pollen and nectar containing nutrients necessary for ... means to stay healthy. , Many recent indicators point to a decline in honey ...
(Date:6/16/2017)... ... June 16, 2017 , ... CTNext , Connecticut’s go-to resource for ... at The LOFT at Chelsea Piers in Stamford. , Nine finalists, all of whom ... judges for an opportunity to secure $10,000 awards to help support business growth. The ...
(Date:6/15/2017)... ... June 15, 2017 , ... The ... an artist’s journey through creative experimentation and interdisciplinary collaboration. Feature Creep, a solo ... 22nd. An opening reception will be held at EKG, located at 3600 Market ...
Breaking Biology Technology: